Feed aggregator

Delaying diabetes with diet and exercise for 4 years results in better long-term health

World Pharma News - Wed, 07/10/2024 - 10:00
Individuals diagnosed with prediabetes can reduce their long-term risk of death and diabetes-related health complications if they delay the onset of diabetes for just four years through diet and exercise. Guangwei Li of the China-Japan Friendship Hospital and colleagues report these findings in a new study published July 9th in the open-access journal PLOS Medicine.

Type 2 diabetes is associated with an increased risk of death and disability, and imposes a significant economic burden on individuals and societies worldwide.

Implantable LED device uses light to treat deep-seated cancers

World Pharma News - Tue, 07/09/2024 - 10:00
Certain types of light have proven to be an effective, minimally invasive treatment for cancers located on or near the skin when combined with a light-activated drug. But deep-seated cancers, surrounded by tissue, blood and bone, have been beyond the reach of light's therapeutic effects.

To bring light's benefits to these harder-to-access cancers, engineers and scientists at the University of Notre Dame have devised a wireless LED device that can be implanted.

Scientists exploring potential new treatments for glioblastoma

World Pharma News - Mon, 07/08/2024 - 10:00
A new approach to treating the most malignant type of brain cancer - glioblastoma - has shown strong promise in pre-clinical settings, raising hopes of increasing current average survival rates beyond 18 months.

Targeted alpha therapy (TAT) is emerging as a potential additional treatment for glioblastoma (GB), a disease which has confounded oncologists for decades due to its aggressive nature and strong resistance to existing therapies.

Boehringer, Zealand Heat Up MASH Race With Strong Phase II Data

Biospace news - Sat, 07/06/2024 - 02:00
Boehringer, Zealand Heat Up MASH Race With Strong Phase II Data 6/7/2024

FDA Raises Concerns About Lilly’s Donanemab Alzheimer’s Candidate Ahead of Adcomm

Biospace news - Sat, 07/06/2024 - 02:00
FDA Raises Concerns About Lilly’s Donanemab Alzheimer’s Candidate Ahead of Adcomm 6/7/2024

FDA Approves Geron’s First-in-Class Telomerase Inhibitor for Blood Disorder

Biospace news - Sat, 07/06/2024 - 02:00
FDA Approves Geron’s First-in-Class Telomerase Inhibitor for Blood Disorder 6/7/2024

Biomea’s Stock Nosedives More Than 60% as FDA Puts Clinical Hold on Diabetes Candidate

Biospace news - Sat, 07/06/2024 - 02:00
Biomea’s Stock Nosedives More Than 60% as FDA Puts Clinical Hold on Diabetes Candidate 6/7/2024

MASH Clash Between Lilly and Boehringer-Zealand Takes Center Stage at EASL24

Biospace news - Sat, 07/06/2024 - 02:00
MASH Clash Between Lilly and Boehringer-Zealand Takes Center Stage at EASL24 6/7/2024

AbbVie Sees Early ROI on $10B Immunogen Buy in Phase II Ovarian Cancer Win

Biospace news - Sat, 07/06/2024 - 02:00
AbbVie Sees Early ROI on $10B Immunogen Buy in Phase II Ovarian Cancer Win 6/7/2024

Vanda Gets $466M Unsolicited Offer from Cycle Amid Ongoing Row with FDA

Biospace news - Sat, 07/06/2024 - 02:00
Vanda Gets $466M Unsolicited Offer from Cycle Amid Ongoing Row with FDA 6/7/2024

Popular prescription weight loss drugs linked to uncommon blinding condition

World Pharma News - Fri, 07/05/2024 - 10:00
A new study led by investigators from Mass Eye and Ear found that patients prescribed semaglutide (as Ozempic or Wegovy) for diabetes or weight loss had a higher risk of having a potentially blinding eye condition called NAION than similar patients who had not been prescribed these drugs.

Notably, the study found people with diabetes who had been prescribed semaglutide by their physician and then filled the prescription were more than four times more likely to be diagnosed with NAION.

Flagship-Backed Prologue Launches with $50M to DELVE into Viral Proteome

Biospace news - Fri, 07/05/2024 - 02:00
Flagship-Backed Prologue Launches with $50M to DELVE into Viral Proteome 5/7/2024

Vertex Touts 13% Revenue Jump, Beats Profit Estimates on Strong Cystic Fibrosis Performance

Biospace news - Fri, 07/05/2024 - 02:00
Vertex Touts 13% Revenue Jump, Beats Profit Estimates on Strong Cystic Fibrosis Performance 5/7/2024

AAV Manufacturing Takes Center Stage at ASGCT24

Biospace news - Fri, 07/05/2024 - 02:00
AAV Manufacturing Takes Center Stage at ASGCT24 5/7/2024

ADC Therapeutics Posts Early Phase II Lymphoma Data for Zynlonta as Revenue Drops 5.8%

Biospace news - Fri, 07/05/2024 - 02:00
ADC Therapeutics Posts Early Phase II Lymphoma Data for Zynlonta as Revenue Drops 5.8% 5/7/2024

Preliminary Findings Point to Low Risk of Secondary Cancers from CAR-T Therapies

Biospace news - Fri, 07/05/2024 - 02:00
Preliminary Findings Point to Low Risk of Secondary Cancers from CAR-T Therapies 5/7/2024

FDA Sets Date for Eli Lilly’s Donanemab Adcomm While Pondering Changes to Format

Biospace news - Fri, 07/05/2024 - 02:00
FDA Sets Date for Eli Lilly’s Donanemab Adcomm While Pondering Changes to Format 5/7/2024

PI3Kγ inhibition circumvents inflammation and vascular leak in SARS-CoV-2 and other infections

World Pharma News - Thu, 07/04/2024 - 10:00
Twelve years ago, cancer researchers at University of California San Diego identified a molecule that helps cancer cells survive by shuttling damaging inflammatory cells into tumor tissue. In new research, they show that the same molecule does the same thing in lung tissue infected with COVID-19 - and that the molecule can be suppressed with a repurposed cancer drug.

GSK and CureVac to restructure collaboration into new licensing agreement

World Pharma News - Wed, 07/03/2024 - 10:00
GSK plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq: CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritise investment and focus their respective mRNA development activities.

Since 2020, GSK and CureVac have worked together to develop mRNA vaccines for infectious diseases.

Scientists turn white fat cells into calorie-burning beige fat

World Pharma News - Tue, 07/02/2024 - 10:00
New UCSF study shows that suppressing a protein turns ordinary fat into a calorie burner and may explain why drug trials attempting the feat haven’t been successful.

Researchers at UC San Francisco have figured out how to turn ordinary white fat cells, which store calories, into beige fat cells that burn calories to maintain body temperature.